ALPS Medical Breakthroughs ETF (SBIO) price, chart and fund profile
Price chart
Fund profile
SBIO tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials.
- Issuer
- ALPS Advisors, Inc.
- Industry
- Healthcare
- Inception
- Dec 30, 2014
- Assets under management
- $241.2M
- Expense ratio
- 0.50%
- Net asset value
- $67.01
- NAV as of
- Aug 28, 2026
- Leverage
- 1×
- Fund page
- www.alpsfunds.com↗
Frequently asked questions
What is ALPS Medical Breakthroughs ETF (SBIO)?
SBIO tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials.
What is SBIO's expense ratio?
ALPS Medical Breakthroughs ETF charges an annual expense ratio of 0.50%. The fund is issued by ALPS Advisors, Inc..
How large is SBIO?
ALPS Medical Breakthroughs ETF manages $241.2M in assets and has traded since Dec 30, 2014.
How do I buy shares of ALPS Medical Breakthroughs ETF (SBIO)?
SBIO trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web dashboard at portal.lighthorse.io, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.
Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.